- Opexa Therapeutics (OPXA -5.2%) plans to execute a public offering of common stock. All shares will be sold by the company.
- Net proceeds will fund the ongoing Abili-T clinical trial in Tcelna patients with secondary progressive MS, preclinical and manufacturing activities for OPX-212 in patients with neuromyelitis optica and potentially an IND to initiate a Phase 1/2 proof-of-concept study.
- Opexa will price the offering shortly.